Last reviewed · How we verify
MB-102 OMID
MB-102 OMID is a CD47 inhibitor Small molecule drug developed by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. It is currently in Phase 3 development for Relapsed or refractory multiple myeloma. Also known as: Relmapirazin.
MB-102 OMID is a monoclonal antibody targeting CD47.
MB-102 OMID is a small molecule used in the treatment of kidney diseases, including kidney injury and kidney failure. It is being studied in a clinical trial (NCT05943977) to evaluate its efficacy and bioequivalence in Chinese participants.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | MB-102 OMID |
|---|---|
| Also known as | Relmapirazin |
| Sponsor | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
| Drug class | CD47 inhibitor |
| Target | CD47 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CD47 is a protein that inhibits phagocytosis, and by targeting it, MB-102 OMID aims to stimulate the immune system to attack cancer cells.
Approved indications
- Relapsed or refractory multiple myeloma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-102 OMID CI brief — competitive landscape report
- MB-102 OMID updates RSS · CI watch RSS
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about MB-102 OMID
What is MB-102 OMID?
How does MB-102 OMID work?
What is MB-102 OMID used for?
Who makes MB-102 OMID?
Is MB-102 OMID also known as anything else?
What drug class is MB-102 OMID in?
What development phase is MB-102 OMID in?
What are the side effects of MB-102 OMID?
What does MB-102 OMID target?
Related
- Drug class: All CD47 inhibitor drugs
- Target: All drugs targeting CD47
- Manufacturer: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory multiple myeloma
- Also known as: Relmapirazin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing